Company Profile
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery (LipAD®) platform with approved active pharmaceutical ingredients (APIs). Our BioSeizer® lipid formulation technology enables both local sustained release and fast onset of APIs at the site of disease or injury with increased pharmacokinetic (PK) control, made possible by customization of lipid layers. Our NanoX® active drug loading technology enables better toxicity profiles, potential for reduced dosing frequency, and enhanced distribution of liposome-encapsulated APIs to the desired site. NanoX® is capable of loading over 50 various compounds.
TLC’s technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need in pain management, ophthalmology and oncology.
Our team has over 150 years of domestic and global experience in lipids and other life sciences products and drug development expertise. Their accomplishments include gaining the approval of two generic lipid formulation products marketed in Asia, including Ampholipad™, the only drug to have proven bioequivalence to Gilead’s AmBisome. We are headquartered in Taipei, Taiwan, with offices in Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco and Tokyo.
Product / Service
- TLC599 (BioSeizer® sustained release dexamethasone sodium phosphate intraarticular injection) for management of osteoarthritis pain.
- TLC590 (BioSeizer® sustained release ropivacaine injection) for management of post-operative pain.
- TLC399 (BioSeizer® sustained release dexamethasone sodium phosphate intraarticular injection) for macular edema due to retinal vein occlusion.
- TLC178 (NanoX® tumor-concentrated delivery of vinorelbine) for rhabdomyosarcoma soft tissue sarcomas & non-small cell lung carcinoma.
- Ampholipad™ (Complex generic of Gilead’s AmBisome® for systemic fungal infections).
Business Interests
Distribution, ODM/OEM, R&D Collaboration, Licensing
Contact Info
Thomas H. Bliss, Jr.
Chief Business Officer
tom_bliss@tlcbio.com
+1-805-300-9970